Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 3 |
2024 | 2 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.
Pharmaceutics. 2024 Apr 8;16(4):513. doi: 10.3390/pharmaceutics16040513.
Pharmaceutics. 2024.
PMID: 38675174
Free PMC article.
Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.
Bezverkhniaia E, Kanellopoulos P, Rosenström U, Tolmachev V, Orlova A.
Bezverkhniaia E, et al.
Int J Mol Sci. 2024 Mar 23;25(7):3615. doi: 10.3390/ijms25073615.
Int J Mol Sci. 2024.
PMID: 38612427
Free PMC article.
Item in Clipboard
Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).
Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, Rosenström U, Tolmachev V, Orlova A.
Bezverkhniaia E, et al.
Int J Mol Sci. 2023 Dec 12;24(24):17391. doi: 10.3390/ijms242417391.
Int J Mol Sci. 2023.
PMID: 38139219
Free PMC article.
Item in Clipboard
Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors.
Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, Doroshenko A, Usynin E, Tashireva L, Vtorushin S, Abouzayed A, Rinne SS, Sörensen J, Tolmachev V, Orlova A.
Chernov V, et al.
Cancers (Basel). 2023 Mar 7;15(6):1631. doi: 10.3390/cancers15061631.
Cancers (Basel). 2023.
PMID: 36980517
Free PMC article.
Item in Clipboard
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity.
Abouzayed A, Borin J, Lundmark F, Rybina A, Hober S, Zelchan R, Tolmachev V, Chernov V, Orlova A.
Abouzayed A, et al.
Diagnostics (Basel). 2023 May 2;13(9):1611. doi: 10.3390/diagnostics13091611.
Diagnostics (Basel). 2023.
PMID: 37175001
Free PMC article.
Item in Clipboard
Cite
Cite